JP2025500481A5 - - Google Patents
Info
- Publication number
- JP2025500481A5 JP2025500481A5 JP2024538257A JP2024538257A JP2025500481A5 JP 2025500481 A5 JP2025500481 A5 JP 2025500481A5 JP 2024538257 A JP2024538257 A JP 2024538257A JP 2024538257 A JP2024538257 A JP 2024538257A JP 2025500481 A5 JP2025500481 A5 JP 2025500481A5
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- composition
- nucleic acid
- use according
- core structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2030217 | 2021-12-22 | ||
| NL2030217 | 2021-12-22 | ||
| PCT/NL2022/050735 WO2023121445A1 (en) | 2021-12-22 | 2022-12-20 | Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500481A JP2025500481A (ja) | 2025-01-09 |
| JP2025500481A5 true JP2025500481A5 (cg-RX-API-DMAC7.html) | 2025-12-23 |
Family
ID=81585487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538257A Pending JP2025500481A (ja) | 2021-12-22 | 2022-12-20 | 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250250564A2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452281A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025500481A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023121445A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2026519131A (ja) * | 2023-06-02 | 2026-06-11 | サプリーム テクノロジーズ,ベー.フェー. | 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン |
| WO2026087695A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for metabolic disorder |
| WO2026087680A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for cardiovascular disease |
| WO2026087678A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for renal disorders |
| WO2026119464A1 (en) | 2024-12-03 | 2026-06-11 | Sapreme Technologies B.V. | Treatment for cns-related disease |
| CN121270643B (zh) * | 2025-12-09 | 2026-03-17 | 成都健腾生物技术有限公司 | 一种麦仙翁皂苷e的生产制备工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| CA2522213A1 (en) * | 2003-04-08 | 2004-10-28 | Dante J. Marciani | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| WO2018080658A1 (en) | 2016-10-27 | 2018-05-03 | Aalborg University | Therapeutic targeting of a microrna to treat duchenne muscular dystrophy |
| KR20240172236A (ko) | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| AU2019315593B2 (en) | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US20220023433A1 (en) | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
| JP7858532B2 (ja) | 2020-01-10 | 2026-05-14 | ダイン セラピューティクス,インコーポレーテッド | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
-
2022
- 2022-12-20 EP EP22830620.5A patent/EP4452281A1/en active Pending
- 2022-12-20 WO PCT/NL2022/050735 patent/WO2023121445A1/en not_active Ceased
- 2022-12-20 JP JP2024538257A patent/JP2025500481A/ja active Pending
- 2022-12-20 US US18/723,163 patent/US20250250564A2/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501610A5 (cg-RX-API-DMAC7.html) | ||
| JP2025500482A5 (cg-RX-API-DMAC7.html) | ||
| ES3052234T3 (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| US8389491B2 (en) | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same | |
| CN118434449A (zh) | 包含用于治疗肌肉消耗障碍的治疗性核酸和靶向皂苷的组合物 | |
| JP7197463B2 (ja) | Smn2の調節のための化合物及び方法 | |
| JP2025500481A (ja) | 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 | |
| EP4592390A1 (en) | Specifically modified rnai reagent and composition | |
| JP2024505151A5 (cg-RX-API-DMAC7.html) | ||
| CN111971051A (zh) | 用增加tm的核苷酸修饰的双链核酸抑制剂分子 | |
| EP4671372A2 (en) | Translation-enhancing nucleic acid compounds: Upward regulation 1 coupled with ASO (ACT-UP1) and their uses | |
| US20230107967A1 (en) | Compositions and methods for inhibiting alpha-1 antitrypsin expression | |
| WO2022092279A1 (ja) | siRNA及び医薬組成物並びに予防及び/又は治療剤 | |
| US20240150768A1 (en) | Methods for the treatment of nash with advanced fibrosis and/or cirrhosis | |
| TW202430192A (zh) | 用於治療nash之劑量方案 | |
| JP7560544B2 (ja) | 遺伝子スプライシングを調節するために有用な化合物および方法 | |
| CN121816200A (zh) | 经由细胞内分子靶标起作用的治疗性效应子组分的改善的治疗方案 | |
| CN121759452A (zh) | 用于抑制MARC1基因表达的siRNA及其缀合物和用途 | |
| HK40118872B (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| HK40118872A (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| HK40129943A (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| CN117120041A (zh) | 胞外囊泡组合物 | |
| HK40008058A (en) | Compounds and methods for modulation of smn2 | |
| HK40008058B (en) | Compounds and methods for modulation of smn2 |